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Abstract Coronary stenting is routinely utilized to treat
symptomatic obstructive coronary artery disease. However,
the efficacy of bare metal coronary stents has been
historically limited by restenosis, which is primarily due
to excessive neointima formation. Drug-eluting stents
(DES) are composed of a stainless steel backbone encom-
passed by a polymer in which a variety of drugs that inhibit
smooth muscle cell proliferation and excessive neointima
formation are incorporated. DES have significantly reduced
the incidence of restenosis but are also associated with a
small (~0.5% per year) but significant risk of late stent
thrombosis. In that regard, estrogen-eluting stents have also
undergone clinical evaluation in reducing restenosis with
the additional potential benefit of enhancing reendothelial-
ization of the stent surface to reduce stent thrombosis.
Estrogen directly promotes vasodilatation, enhances endo-
thelial healing, and prevents smooth muscle cell migration
and proliferation. Due to these mechanisms, estrogen has
been postulated to reduce neointimal hyperplasia without
delaying endothelial healing. In animal studies, estrogen
treatment was effective in decreasing neointimal hyperpla-
sia after both balloon angioplasty and stenting regardless of
the method of drug delivery. The first uncontrolled human
study using estrogen-coated stents demonstrated acceptable
efficacy in reducing late lumen loss. However, subsequent
randomized clinical trials did not show superiority of
estrogen-eluting stents over bare metal stents or DES.
Further studies are required to determine optimal dose and
method of estrogen delivery with coronary stenting and
whether this approach will be a viable alternative to the
current DES armamentarium.
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Effects of Estrogens on Blood Vessels
Various cardioprotective properties of estrogens have been
reported for decades [1]. One major beneficial effect is the
improvement in the lipid profile with reduction of total and
low-density lipoprotein cholesterol and increases in high-
density lipoprotein cholesterol in postmenopausal women
[2, 3]. Furthermore, in a recent study of 27,736 women,
estrogen replacement was associated with significantly
lower levels of lipoprotein(a) [4]. Estrogen also reduces
fibrinogen and plasminogen activator inhibitor 1 levels,
suggesting that it may possess enhanced fibrinolytic
potential [5, 6]. However, in the randomized, double-
blind, placebo-controlled Heart and Estrogen/progestin
Replacement Study trial testing the efficacy and safety of
estrogen plus progestin therapy for prevention of recurrent
coronary heart disease (CHD) events in women, hormone
replacement therapy did not reduce the incidence of CHD
[7]. Unexpectedly, it did significantly increase the incidence
of thromboembolic events compared to placebo.
Balloon angioplasty and stent placement routinely result
in almost complete loss of the endothelial surface overlying
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reendothelialization occurs by islets of endothelial cells
dividingandfillinginthegagsoverthe injuredsubendothelial
surface, which is an important factor in the recovery of the
vessel wall from vascular injury [8]. This is particularly
relevant in DES, where reendothelialization can be delayed
or even prevented altogether, resulting in potential adverse
effects [9]. Rapid reendothelialization prevents various
unfavorable processes of vessel healing like smooth muscle
cell (SMC) migration, excessive neointimal growth, and
endothelial dysfunction. Estrogen promotes reendothelializa-
tion by enhancing vascular endothelial growth factor gene
expression [10–12] and directly increases synthesis of nitric
oxide (NO) with resultant vasodilatory effects and inhibition
of SMC proliferation [1].
Rationale for Development of Estrogen-Eluting Stents
Intracoronary stenting is widely used for the treatment of
obstructive coronary artery disease. Although stenting
reduces the restenosis rate compared to balloon angioplasty
[13, 14], neointimal proliferation after bare metal stenting
still limits its efficacy. Endothelial cells control some
aspects of the growth of SMC by release of NO, which
has a growth-inhibitory effect, and blocks SMC which from
circulating growth factors and secreting matrix proteins and
proteoglycans. Following coronary stenting, the neointima
generated is generally proportional to the degree of
endothelial damage [8, 15]. Rapid endothelialization can
prevent overgrowth of neointima, a major mechanism of in-
stent restenosis. Therefore, promotion of endothelialization
after stenting could be helpful in limiting in-stent reste-
nosis.
DES have significantly reduced the rate of restenosis and
subsequent target lesion revascularization compared to bare
metal stents [16, 17]. The current formulations of DES are
composed of stainless steel or cobalt chromium struts to
which is attached a nondissolvable polymer imbedded with
a variety of lipophilic drugs from the limus family
(sirolimus, everolimus, zotarolimus, biolimus) or paclitaxel,
which are either cytostatic or cytotoxic to SMC. These
effects result in significant inhibition of SMC proliferation
and ultimately in a reduction of excessive neointima
formation. However, these drugs may also interfere with
the normal healing mechanism of endothelialization after
stent placement which may lead to increased risk of late
stent thrombosis [18–21]. Unlike the drugs used in DES,
estrogen could prevent restenosis by promoting endothelial
healing and preventing SMC proliferation. Therefore,
Fig. 1 The unique microporous surface of the ISAR stent platform
allows for drug deposition and retards drug release without obligate
application of a polymer. The roughness of the stent surface as
determined by perthometer is 1.96±0.21µm. Various kinds of drugs or
drug combinations including rapamycin and estrogen can be loaded on
ISAR stent with the same mechanism. A Uncoated microporous stent
under a magnification of ×400 illustrating the rough surface achieved
by mechanical treatment. The open-cell stent design is illustrated on
the small photograph on the upper left corner. B Expanded microporous
stent coated with 0.5% rapamycin solution (gold-sputtered to improve
visibility, ×200), visually highlighting uniform drug distribution across
the entire stent surface. The surface of a noncoated (C) and rapamycin-
coated (D) microporous stent at a magnification of ×1,000. Reprinted
with permission from Wessely et al. [22]
J. of Cardiovasc. Trans. Res. (2009) 2:240–244 241several groups have generated estrogen-eluting stents for
the prevention of restenosis. A description of an example of
estrogen-eluting stents is shown in Fig. 1 [22]. The ISAR
stent platform can deliver drugs such as rapamycin and
estrogen. With its microporous surface, estrogen can be
attached to the stent and released slowly.
Animal Studies with Estrogen Stents
In 1981, Beldekas et al. [23] reported that bovine aortic
SMC cultured with 17-β-estradiol (17βE) had reduced
production of collagen. Chandrasekar et al. [24] showed
that local delivery of 600µg 17βE reduced both the
proliferative activity of SMC as well as neointimal
hyperplasia after balloon injury of porcine coronary arteries
[25]. New et al. [26] took this a step further by using a
phosphorylcholine (PC)-coated estrogen-eluting stent and
demonstrated a reduction in neointimal hyperplasia without
delaying reendothelialization. A recent study using a
similar porcine model [27] showed that intracoronary
estrogen delivery using the InfusaSleeve catheter decreased
percent stenosis by 47% (30→16%) in balloon group and
23% (71→55%) in stent group. In addition, type 1 collagen
significantly correlated with the vessel wall injury scale and
was reduced in the 17βE group. Overall, although
publication bias cannot be ruled out, these experimental
studies suggested a strong rationale for moving forward and
assessing the role of estrogen-eluting stents in patients. It is
also to be emphasized that many experimental studies are
positive in animal models of restenosis, such as the rat
carotid artery, rabbit iliac, and pig coronary arteries, but that
the vast majority of compounds used in these models have
not been successful in clinical trials.
Human Studies with Estrogen Stents
Table 1 describes the clinical studies evaluating estrogen
coated stents. The first human study evaluating an estrogen-
coated stent used the BiodivYsio™ stent, where 17βE was
loaded onto the stent just prior to insertion into the patients
by dipping itin an estrogen solution.The BiodivYsio™ stent
is a stainless steel stent coated with phosphorylcholine, which
is present on phospholipids on the surface of cell membranes,
to presumably optimize biocompatibility, although this has
not been definitively demonstrated clinically. The Estrogen
And Stents To Eliminate Restenosis (EASTER) trial [28]w a s
Table 1 Summary of clinical trials on estrogen-eluting stents
Author Year No. Duration
of dual
antiplatelet
therapy
Study design Method of drug
coating
End point Results Stent
thrombosis
Abizaid
et al. [28]
(EASTER)
2004 30 60 days
(clopidogrel
75 mg)
Single center,
no control
group
On-site coating,
PC coat on
BiodivYsio™
stent 2.52-μg/mm
2
stent surface
12-month clinical
data 6- month
coronary
angiography
and IVUS
Good (late loss
0.54±0.44 mm)
None
Airoldi
et al. [30]
2005 108 12 weeks
(ticlopidine
500 mg or
clopidogrel
75 mg)
Multicenter
randomized
17βEo nP C
coat vs. PC
coat only
Precoated
2.52-μg/mm
2
stent surface
12-month clinical
data 6-month
coronary
angiography
and IVUS
No difference in
clinical and
angiographic
outcome
3 deaths or MI in
PC coat group/no
death or MI in
estrogen group
Abizaid
et al. [31]
(ETHOS-1)
2007 95 2 months
(ticlopidine
500 mg or
clopidogrel
75 mg)
Randomized,
double-blind,
multicenter
control vs.
slow release
vs. moderate
release
Precoated 250μg/
15 mm of stent
length, moderate
release 50% in
1 day, slow
release 50% in
8 days
6-month percent
volume obstruction
by IVUS, clinical
outcome of
6 months
No difference
in %VO/no
difference
in clinical
outcome
Slow-release group
1 death/1 MI,
control and
moderate
release group no
death or MI
Adriaenssens
et al. [32]
(ISAR-PEACE)
2007 502 6 months
(clopidogrel
75 mg)
Randomized
rapamycin
vs. estradiol
plus rapamycin-
eluting stent
On-site coating, none
PC coat, stainless
steel stent with
micropore/95%
RES, 60% ERES
release in 1 month
Primary: six month
in-stent
late lumen loss,
secondary:
binary restenosis,
TVR, death,
nonfatal MI
No difference in
late lumen loss
and binary
restenosis rate/no
difference in
clinical outcome
ERES 2 patients/
RES 3 patients
RES rapamycin-eluting stent, ERES estrogen–rapamycin-eluting stent, IVUS intravascular ultrasound, 17βE 17-β-estradiol, PC phosphorylcho-
line, VO volume obstruction, MI myocardial infarction
242 J. of Cardiovasc. Trans. Res. (2009) 2:240–244a single-center study of 30 patient study in which short
(<18 mm), single, de novo lesions were treated. In this initial
feasibilitystudy,thenumberofpatientswassmall;therewasno
control group; instead, each patient was used as their own
control. With this version of the stent, drug was released for
only the first 24 h. Manual drug-loading methods may lack
reproducibilityandlikelylimittheamountloadedontothestent
and also result in rapid loss of estrogen from the stent once
implanted in the coronary artery.
Six-month angiographic and intravascular ultrasound
(IVUS) was performed and clinical follow-up was obtained
at 12 months. The 6-month late luminal loss, defined as the
minimal lumen diameter (MLD) at the end of the procedure
minus the MLD at follow-up (6–9 months) angiography, was
0.54±0.44 mm, which is less than the reported late loss of
0.95±0.61 mm with a PC-coated BiodivYsio™ stent without
estrogen loading and also similar to results obtained with
other bare metal stents [29]. The late loss was still greater
than previously noted with the paclitaxel and sirolimus-
eluting stents [16, 17]. Binary restenosis (diameter stenosis>
50%), another angiographic indicator of stent efficacy,
occurred in only two patients and there were no major
adverse cardiovascular events (MACE) reported at 12-month
clinical follow-up. Neointimal hyperplasia as measured by
IVUS was also significantly reduced compared to bare metal
stents. Dual antiplatelet therapy was prescribed for only
60 days but there were no stent thromboses.
The next human trial was a randomized multicenter
study in 104 patients in which preloaded 17βE-eluting PC-
coated BiodivYsio™ stents were used [30]. Study inclusion
and exclusion criteria were similar to the EASTER trial but
longer lesions (<40 mm) in larger diameter vessels (4 mm)
were treated. Dual antiplatelet therapy (ticlopidine 500 mg
daily and aspirin 100 mg daily) was administered for
12 weeks. There were no significant differences between
the BiodivYsio™ stent without estrogen loading and the
estrogen-coated BiodivYsio™ stent in late lumen loss,
binary restenosis rate, or MACE rates. Overall, this study
demonstrated safety and feasibility of 17βE-eluting stents,
but there was no superiority over the control group.
The estradiol-eluting stents in humans for restenosis trial
(ETHOS-1) [31] performed by the same research group as the
EASTER trial was a randomized multicenter study randomiz-
ing three groups of subjects: a control BiodivYsio™ stent
without estrogen and two formulations of the BiodivYsio™
stent coated with 17βE in a slow versus moderate
programmed-release preparation. To optimize short-term and
long-term action of estrogen, approximately 50% of drug was
released within 1 day in the moderate-release and 8 days in the
slow-release groups, with the remainder of the drug eluted over
30 days. The estrogen dose was 240µg/15 mm of stent length,
representing the maximum dose that could be implanted on the
stent. Oral clopidogrel was administered for 60 days. The main
result of the study was that no differences in any efficacy
measures were noted between the two groups at the 6-month
angiographic and IVUS evaluation revealed
Inthemostrecentlypublishedhumanstudy,ISAR-PEACE,
theadditiveeffectofestrogenonarapamycin-elutingstentwas
evaluated [32]. To deliver the drugs, a polymer-free stainless
steel stent with micropores was used. Dual antiplatelet
therapy with aspirin and clopidogrel was done for 6 months.
The primary end point was late lumen loss. In 250 patients,
rapamycin-eluting stents (RES) were deployed and in 252
patients rapamycin plus estrogen-eluting stents (ERES) were
deployed. Late lumen loss was not significantly different
between the two groups (ERES 0.52±0.58 mm, RES 0.51±
0.58 mm). The incidence of binary restenosis and stent
thrombosis were not significantly different. Because an IVUS
analysis was not performed, the effect of estrogen on
neointima formation could not be evaluated.
Conclusions
In summary, human stent trials evaluating estrogen-eluting
stents did not show any significant benefit over bare metal
stents as suggested by animal studies. Although the animal
models of restenosis and initial uncontrolled clinical studies
were initially very promising, recent well-designed clinical
trialshave not show equivalence or superiorityoverbaremetal
stents or to have an additive efficacy when incorporated on
existingDES.Despitetheoreticalvascularbenefitsofestrogen,
no definitive explanation for the failure of estrogen-eluting
stentsinpreventingrestenosishasbeenprovided.Basedonthe
above studies, it is unlikely that estrogen-eluting stents will
become clinically available without some new fundamental
improvements in potency of estrogen compounds, elution
kinetics, and/or improvements in stent design and incorpora-
tion of estrogen compounds.
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